Danco Laboratories is urging the Supreme Court to pause a 5th Circuit ruling that abruptly ended mail-access for medication abortion.
Danco Laboratories filed an emergency appeal with the Supreme Court on Saturday, seeking to block a lower-court ruling that halted mail-order access to mifepristone. The 5th Circuit Court of Appeals reinstated a mandate requiring the drug be obtained in person, threatening the telehealth model used for 60% of U.S. abortions.
Attorneys warned that the sudden restriction “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” They questioned the logistics for patients currently mid-treatment: “What happens when patients arrive for scheduled appointments this weekend… What should a patient do if she cannot obtain an in-person appointment immediately?”
Despite data showing the drug is safer than penicillin, this conservative legal challenge forces the high court to revisit reproductive rights once more.
NEWS NOW:
